TB 511
Alternative Names: TB-511Latest Information Update: 05 Jul 2024
At a glance
- Originator Twinpig Biolab
- Class Antineoplastics; Peptide drug conjugates
- Mechanism of Action Apoptosis stimulants; Tumour associated macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 14 May 2024 Twinpig Biolab has patent pending applications for TB 511 in Canada, the European Union and China
- 14 May 2024 Twinpig Biolab has patent protection for TB 511 in the US, Japan, South Korea, India and Australia
- 14 May 2024 Phase-I clinical trials in Cancer (SC) prior to May 2024 (Twinpig Biolab Pipeline, May 2024)